We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Myhealthchecked Plc | MHC | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 12.00 | 08:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 12.00 | 12.00 | 12.00 | 12.00 | 12.00 |
| Industry Sector |
|---|
| HEALTH CARE EQUIPMENT & SERVICES |
| Top Posts |
|---|
Posted at 23/11/2024 12:02 by tia01 Penny appears to have got to grips with the manufacturing issues and the restocking in Boots is already underway. Recent price drop in share price is quite healthy as it’s enabled newbie’s to get in or LTHs to top up. I took advantage yesterday with a top up but who knows. I’m in for the long term and journey and if we get the phlebotomy testing deal over the line at Boots this could easily be a multi bagger imo. That’s the key for me as we move away from COVID revenue and we all know the NHS GP situation is getting worse so will Labour do the right thing to solve this by utilising Boots and MHC facilities!. Digital Data is the way forward and MHC is leading the charge so short term pain in pullbacks is long term gain in my eyes.Let’s hope for a little news during Christmas season. Good luck all and remember not many AIM companies still have cash to fund next phase as we do!. |
Posted at 11/11/2024 09:32 by tia01 Time for some activity.Will MHC start some promotions or are they just trying to save cash!. Talk on Tv this morning regarding GP appointment problems. Can Boots and MHC strike a deal to over come this issue!. Surely deal for phlebotomy must be close. Early 2025! |
Posted at 27/10/2024 08:13 by tia01 DualWe know MHC has big plans and clearly in the middle of a deal that is game changing. It will clearly involve Boots and possibly government changes to pharmacy first products available to be used in stores with Boots specialists. The Poc Doc deal is significant also as it will also be sold over the counter or off the shelf. It’s all suggesting that one of the biggest killers in heart disease is a major focus so I personally see heart tests being added to the pharmacy first list. I could be wrong but the government know Boots with MHC tests and digital data can solve the GP appointment problems. Save costs and more efficient and save lives. MHC are focusing on LFT tests IMO which is why they ain’t restocked VITAMIN D tests as no margins in them. I also see a surprise and do wonder if Newfoundland may try a cheap takeover of MHC. They already supply the LFT tests and HIV tests to Boots via MHC!. They are also in many major shops but can’t get in Boots without MHC who have the required approval as you pointed out. Boots is extremely strict which is why it hasn’t stocked the prostrate tests because of the trauma it could cause after a positive test result etc. I think this may change as it’s a big issue. Chris Hoy a true ambassador and legend highlighting the need for more testing is testament to why Boots and MHC need to combine to offer a testing service to the public for NHS patients. Also note many black Caribbean suffer prostrate issues so Boots and MHC could use marketing to target the ethnic communities by highlighting this!. Anyway don’t expect and deal until the new year because of the parties involved and complexity involved. I do anticipate a market campaign to start in November to coincide with the run up to Christmas and the deal that will be announced in the new year hopefully. The focus on Covid revenue has clearly shifted towards testing and the question is can MHC get the revenue breaking deal done without a share dilution required!. I think the answer is 100 YES but equally a VAT refund will ensure the answer is yes. Also note Directors can’t buy until the deal is announced. Once again will Newfoundland be ambitious and smart enough to launch a strike for MHC knowing the potential benefits to both parties. Would MHC make a play for Newfoundland!!!! |
Posted at 11/9/2024 18:02 by tia01 I seriously don’t think Penny believes there’s any money in LFT tests other than Covid ones.Fact is I’m Sure Newfoundland provide MHC with its LFT tests so I guess it’s hard for MHC to compete with them on those tests. MHC clearly focused on phlebotomy testing and I feel a deal with Boots to supply tests for NHS patients. GPs have made the government realise they need a new approach otherwise waiting lists will get even longer and waiting time also. I just feel the share price is suffering as a result of the wait for news. I don’t know what the value of Newfoundland is but could a Merger with MHC really make sense given one is focused more on LFT and the other phlebotomy tests. Time for Penny to deliver something really exciting to share so we can all go to the River Wye to celebrate lol. |
Posted at 08/9/2024 20:56 by tia01 Muck166hxxps://news.sky.com I think MHC has definitely been dependent on Covid revenue however we must remember that has been vital to allow us to enact a growth plan without dilution to shareholders. 2, It’s allowed us to produce products that are growing in added revenue streams however this will take a while to bed in as customers are educated on the benefits of self testing. 3, Revenue in Covid products will probably show a decline but we don’t know much stock was paid for prior to the figures due this month. 4, costs definitely associated with implementing products in over 200 news Boots branches. This will help revenue moving forward on new products. 5, If the report suggests anything regarding patients being affected by GPs cancellations etc MHC could benefit if it’s decided it’s financially beneficial to the NHS to allow more testing in Boots under a criteria that meets the requirements. Penny has alluded to this in the investor meeting and said any decision needs to be cost effective to the NHS. Is this the news Penny can’t share as yet in her linked in cryptic update!. This would be game changing for MHC if the new tests were added to pharmacy first or phlebotomy tests allowed in Boots to elevate GPs stress. MHC has invested in Digital technology heavy so you have questions why and the plans given the financial costs. My belief is they know a new government will want to demonstrate a move from GP dependance. 100% believe Penny has some big news for plans with Boots and this why she’s concentrating on a strategy with Boots. |
Posted at 27/8/2024 11:32 by muck166 Tia - I don't want to get in a spat with you about valuations, especially on the MHC board. And I am not saying MHC is a bad company - it isn't.Yes, ABDX supplies Boots with some own label tests. In fact, they are exactly the same Chinese tests that MHC also sell through Boots, just in different packaging. And yes, ABDX makes and sells pregnancy tests, as well as other tests. But even a cursory look at its accounts will show you that revenue it makes from total product sales is less than 10% of its total revenue. The bulk of its revenue comes from CDMO/CRO activities on a fee for service model, ie it helps third party lateral flow developers move an idea to a commercial, approved LFT product that can be manufactured at scale and robustly. That is its main business, and its NOT the same as MHC. I don't know why MHC has an MCAP of less than ABDX, but if I were to guess I would say it's because MHC remains heavily reliant on COVID revenue (which is falling) and seems to be stagnating rather than growing, whereas ABDX has growing revenue from a multitude of different customers and streams, as well as some huge potential in its pipe. There are very good reasons why 3 institutional investors took almost all of the recent raise at less than a 10% discount - I assume it's because they see real growth potential in ABDX. Sadly, MHC isn't showing investors anything at the moment. |
Posted at 21/8/2024 18:16 by tia01 MuckI don’t see Albington has being completely different!. Most revenue derived from a pregnancy test where MHC started life. Albington providing tests to Boots in Boots brand that MHC does in own brand. Mhc in a better state financially and remember revenue is revenue and profit is profit. However the companies are extremely similar and I’m sure mHC/concepta sold Albington it current testing premises!. I feel the financial position of MHC is 100x healthier and any one knows revenue isn’t profit |
Posted at 07/8/2024 08:46 by tia01 My advice is trust in Penny. Penny has done what said from the days of Covid. I’m a person who only invested in MHC because I truly understood the long term picture. I also genuinely researched Penny and believed her CV truly showed she was the best person to deliver us growth. I am equally frustrated with the time frame however MHC has invested in technology and products at the infancy stage to the public. It’s a huge risk however if they pull it off and deals are done we could be truly well undervalued. Penny offer an update soon as we are in closed period. I’m looking for an update on growth plans and demonstrations that MHC is focused on shareholders value without dilution. As I’ve said 100 times companies like GDR,UKOG and HE1 have recently saw shares rocket but people fail to realise they have all been diluted to values leave original investors LTHs with paperless values. MHC have been prudent at the expense of going for revenue growth rather growing with a partnership with Boots. Whilst we haven’t seen the huge benefit of this i trust Penny when she says give it time. A genuine CEO in my opinion who will prove to be worth the patience. We do need deals soon in my opinion and will get them in 2024 |
Posted at 30/6/2024 08:52 by tia01 I took this morning to read the Chairman’s Statement and it’s clear a slowdown is expected in Covid tests in the first half of 2024.Is it all bad news! I personally see a slowdown that will see sales of Covid for first six months of 2024 to come in at around 3m based on 1 test being sold in each of the 1900 stores nationwide and also online sales during the period. You may think ouch but as stated in Chairman’s statement a decline is expected. The good thing is it’s evident the other tests provided by MHC will make up for lost revenue from the Covid tests as sales increase. I don’t expect a huge amount of revenue from new tests but it’s reasonable to expect between half a million and three quarters in the first half. So I would anticipate a similar overall figure to the first half in 2023 with combined sales and wellness tests. The key will be any update that may lead to an anticipated huge uptick in wellness test sales in Boots. We are expanding to another 200plus stores with wellness tests however this will come at a cost to MHC for the initial costs of shelving and stock etc. It will however add to the long term growth of revenue. It’s also self funded. I do expect strong cost control to reserve cash and also believe any collaboration with Boots pharmacy first and phlebotomy testing privately within Boots instore MOT services available could provide a catalyst needed. I don’t think a buy back will be announced although it would be a great idea. I believe the company will prioritise using cash for growing the business instead. I believe MHC should use Tik Tok content creators who advertise for free and at a cost of MHC sending a free sample to demonstrate. Of course MHC would need to sell the products on TIk Tok shop in order for content creators to access them and offer free promotions. TIk Tok viewers are probably between 16 to 40 but many of the tests are geared towards these ages and then we must remember that all these 18-40s have older family members they may buy a test for. Remember if you give a free test to 20 Tik Tok members who each have 20,000 plus followers for example that a potential sale to 400,000 off just 20 free samples! Times this by 50 free samples etc you see how quick it would be to get the brand out there for literally nothing. Then you have the benefits of being on TIK TOK shop. This would be great if they have a deal with Boots and use Tik Tok viewers to make people aware of the products and services etc. It would also help encourage direct sales to MHC and enhance the user rate of the digital data. MHC must be smart a use the 8m of cash wisely to gain traction to wellness tests which are the future of the business whilst Covid revenue is this available. Covid revenue is the key to growth without dilution and valuable for MHC. A recent surge in Covid cases will reflect in 2nd half results in my opinion as Boots will buy tests in advance based on the figures and projections to ensure they are stocked for winter 2024 and summer 2024. The market will only react to news flow from MHC which is expected imminently. Penny has a great opportunity to demonstrate the future of wellness testing combined with the importance of digital data which Poc Doc has demonstrated is the future |
Posted at 18/3/2024 07:55 by tia01 After comparing MHC and ABDX you can’t help notice quite a few points.ABDX market cap over 10m MHC over 6.5m ABDX has around 1.9m MHC has around 8m plus ABDX has a high cash burn and needed fund raises. MHC is prudent and cash in the bank growing. ABDX concentrated on revenue growth. MHC concentrated on cash flow and growth. ABDX main product is salistick MHC has over 20 Products So is ABDX Market Cap of 10m justified! Or is MHCs 6.5m way undervalued! Hopefully end of year results will show growth for MHC and we push up to levels of our competitors to reflect the facts. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
